Literature DB >> 22983113

Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population.

Fred S Apple1, Ranka Ler, MaryAnn M Murakami.   

Abstract

BACKGROUND: Between-assay comparability of 99th percentiles for cardiac troponin concentrations has not been assessed systematically in a single population for a large number of assays.
METHODS: We determined 99th percentiles for 19 cardiac troponin assays in heparin plasma samples from a population of 272 and 252 presumably healthy males and females, respectively. The assays evaluated included 1 cardiac troponin T (cTnT) assay from Roche and 18 cTnI assays from Abbott, Alere, Beckman, bioMerieux, Instrumentation Laboratory, Ortho-Clinical Diagnostics, Singulex, Siemens, and Roche. Five of these assays were categorized as high-sensitivity, 9 as sensitive-contemporary, and 5 as point-of-care (POC) assays.
RESULTS: For high-sensitivity cTnI (hs-cTnI) assays 99th percentiles varied from 23 to 58 ng/L. At least 80% of individuals had measurable hs-cTnI, whereas only 25% had measurable high-sensitivity cTnT. All high-sensitivity cardic troponin assays had 99th percentiles that were 1.2-2.4-fold higher in males than females. For the 9 sensitive-contemporary cTnI assays, 99th percentiles varied from 12 to 392 ng/L, and only the Beckman assay gave measurable concentrations in a substantial portion of the population (35% vs ≤6% for the others). Seven of these 9 assays had 1.3-5.0-fold higher 99th percentiles for males than females. For 5 cTnI POC assays, 99th percentiles varied from <10 to 40 ng/L. The Instrumentation Laboratory assay gave measurable results in 27.8% of study participants vs ≤6% for the others. Correlations were generally poor among assays.
CONCLUSIONS: Among cardiac troponin assays 99th percentile concentrations appear to differ. High-sensitivity assays provide measurable cardiac troponin results in a substantially greater fraction of presumably healthy individuals.
© 2012 American Association for Clinical Chemistry

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22983113     DOI: 10.1373/clinchem.2012.192716

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  116 in total

1.  Prevalence and Prognostic Association of Circulating Troponin in the Acute Respiratory Distress Syndrome.

Authors:  Thomas S Metkus; Eliseo Guallar; Lori Sokoll; David Morrow; Gordon Tomaselli; Roy Brower; Steven Schulman; Frederick K Korley
Journal:  Crit Care Med       Date:  2017-10       Impact factor: 7.598

Review 2.  Pre-analytic variability in cardiovascular biomarker testing.

Authors:  Roberto Cemin; Massimo Daves
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

3.  Use of the HEART Pathway with high sensitivity cardiac troponins: A secondary analysis.

Authors:  Simon A Mahler; Jason P Stopyra; Fred S Apple; Robert F Riley; Gregory B Russell; Brian C Hiestand; James W Hoekstra; Cedric W Lefebvre; Bret A Nicks; David M Cline; Kim L Askew; David M Herrington; Gregory L Burke; Chadwick D Miller
Journal:  Clin Biochem       Date:  2017-01-10       Impact factor: 3.281

4.  B-Type Natriuretic Peptide and Cardiac Troponin I Are Associated With Adverse Outcomes in Stable Kidney Transplant Recipients.

Authors:  Petr Jarolim; Brian L Claggett; Michael J Conrad; Myra A Carpenter; Anastasia Ivanova; Andrew G Bostom; John W Kusek; Lawrence G Hunsicker; Paul F Jacques; Lisa Gravens-Mueller; Peter Finn; Scott D Solomon; Daniel E Weiner; Andrew S Levey; Marc A Pfeffer
Journal:  Transplantation       Date:  2017-01       Impact factor: 4.939

5.  Early diagnosis of acute myocardial infarction in patients with mild elevations of cardiac troponin.

Authors:  Jasper Boeddinghaus; Tobias Reichlin; Thomas Nestelberger; Raphael Twerenbold; Yvette Meili; Karin Wildi; Petra Hillinger; Maria Rubini Giménez; Janosch Cupa; Lukas Schumacher; Marie Schubera; Patrick Badertscher; Sydney Corbière; Karin Grimm; Christian Puelacher; Zaid Sabti; Dayana Flores Widmer; Nicolas Schaerli; Nikola Kozhuharov; Samyut Shrestha; Tobias Bürge; Patrick Mächler; Michael Büchi; Katharina Rentsch; Òscar Miró; Beatriz López; F Javier Martin-Sanchez; Esther Rodriguez-Adrada; Beata Morawiec; Damian Kawecki; Eva Ganovská; Jiri Parenica; Jens Lohrmann; Andreas Buser; Dagmar I Keller; Stefan Osswald; Christian Mueller
Journal:  Clin Res Cardiol       Date:  2017-02-01       Impact factor: 5.460

6.  Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.

Authors:  Ryunosuke Okuyama; Junnichi Ishii; Hiroshi Takahashi; Hideki Kawai; Takashi Muramatsu; Masahide Harada; Akira Yamada; Sadako Motoyama; Shigeru Matsui; Hiroyuki Naruse; Masayoshi Sarai; Midori Hasegawa; Eiichi Watanabe; Atsushi Suzuki; Mutsuharu Hayashi; Hideo Izawa; Yukio Yuzawa; Yukio Ozaki
Journal:  Heart Vessels       Date:  2017-02-02       Impact factor: 2.037

7.  Prognostic comparison of different sensitivity cardiac troponin assays in stable heart failure.

Authors:  Justin L Grodin; Sarah Neale; Yuping Wu; Stanley L Hazen; W H Wilson Tang
Journal:  Am J Med       Date:  2014-10-15       Impact factor: 4.965

Review 8.  High-sensitivity cardiac troponins in everyday clinical practice.

Authors:  Johannes Mair
Journal:  World J Cardiol       Date:  2014-04-26

9.  Obstructive sleep apnea: no independent association to troponins.

Authors:  Trygve Sørdahl Hall; Tobias Herrscher; Petr Jarolim; Morten W Fagerland; Torstein Jensen; Jonas Hallén; Stefan Agewall; Dan Atar
Journal:  Sleep Breath       Date:  2013-09-17       Impact factor: 2.816

10.  Postoperative high-sensitivity troponin T as a predictor of sudden cardiac arrest in patients undergoing cardiac surgery.

Authors:  Piotr Duchnowski; Tomasz Hryniewiecki; Mariusz Kuśmierczyk; Piotr Szymański
Journal:  Cardiol J       Date:  2019-01-31       Impact factor: 2.737

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.